Section 50 of the Inflation Reduction Act Drug Price Negotiation Program: Considerations for the Centers for Medicare Medicaid Services, Manufacturers, and the Health Economics and Outcomes Research Community Read more about Section 50 of the Inflation Reduction Act Drug Price Negotiation Program: Considerations for the Centers for Medicare Medicaid Services, Manufacturers, and the Health Economics and Outcomes Research Community
How the Inflation Reduction Act Could Delay Pharmaceutical Launches, Reduce Indications, and Chill Evidence Generation Read more about How the Inflation Reduction Act Could Delay Pharmaceutical Launches, Reduce Indications, and Chill Evidence Generation
Addressing Critical Ambiguities in CMS’s Drug Evaluation Process Read more about Addressing Critical Ambiguities in CMS’s Drug Evaluation Process
Getting Patient Input Right During the IRA Implementation Read more about Getting Patient Input Right During the IRA Implementation
NPC Submits Comments to CMS on Medicaid Drug Rebate Program Read more about NPC Submits Comments to CMS on Medicaid Drug Rebate Program
Value-Based Performance Arrangements for Chronic Conditions: An Economic Simulation of Medicaid Drug Rebate Program Reforms Read more about Value-Based Performance Arrangements for Chronic Conditions: An Economic Simulation of Medicaid Drug Rebate Program Reforms